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ABSTRACT 
Background: Increasing numbers of older adults are living with kidney disease.  For those with 
comorbidities, conservative management of end-stage kidney disease is a viable option: dialysis may 
afford limited or no survival benefit, and perceived burdens may outweigh benefits. Conservative 
management focuses on: maintaining remaining kidney function; symptom management; and quality 
of life. Common symptoms in conservatively managed kidney disease include: fatigue, anorexia, 
nausea and vomiting, pain and pruritis. Chronic disease is associated with biographical disruption and 
a loss of sense of self. Coping strategies are shaped by illness perceptions, but little is known of illness 
perceptions of people living with conservatively managed kidney disease. This study aimed to explore 
the experience, impact and understanding of conservatively managed end-stage kidney disease 
among older adults.   
Methods: Secondary analysis of qualitative interviews analysed using thematic analysis. Twenty 
people with conservatively managed end-stage kidney disease were recruited from 3 UK renal units: 
median age was 82 (range 69-95); 9 women, 11 men. 
Results: Participants described the invisibility and intangibility of kidney disease, and challenges in 
attributing symptoms to the disease.  They described a spectre-like presence, sapping their energy 
and holding them down. For some, it was hard to differentiate symptoms of the illness from 
characteristics of aging, resulting in challenges in illness attribution, and disconnectedness from the 
illness.   
Conclusions: Participants described challenges in attributing their symptoms to kidney disease which 
negatively impacted upon their wellbeing, and ability to accept an adjusted sense of self.  
Understanding these challenges is critical in the management conditions such as end-stage kidney 
disease where prognosis may be poor, and where an increase in symptom distress may suggest a 
marked deterioration in their condition, or a change in phase of illness.  Clinical services need to 
recognize the illness experience (alongside more symptom led approaches), including the invisibility, 
intangibility, and disconnectedness, and address this through specific interventions focused on 
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improving clinical assessment, communication and education, alongside peer and professional 
support. 
Keywords (max 5): end-stage kidney disease, conservative care, palliative care, qualitative research 
 
INTRODUCTION 
Over the last decade the number of people dying from Chronic Kidney Disease has increased by almost 
one third (25.5-31.4%); this equates to approximately 1.2 million people dying each year from kidney 
disease globally (1). There has also been a marked shift towards deaths at older ages since the 1990s 
(1), and the end-stage kidney disease population is increasingly elderly and co-morbid (2).     
 
For older adults facing a decision regarding renal replacement therapy, although survival in receipt of 
dialysis will most likely be longer, the burden of accessing dialysis may outweigh the survival benefit 
for some patients (3).  Dialysis impacts heavily on quality of life requiring frequent hospital attendance 
(86% receive haemodialysis in hospital, 14% at home), usually three times per week (4). Conservative 
kidney management is considered a viable and beneficial option for older adults with comorbidities, 
particularly ischemic heart disease, for whom survival benefit of dialysis may be negligible (5-7).  
Patients receiving conservative management spend less time having treatment, and are less likely to 
require hospital admissions or die in hospital (8).  However, access to and awareness of conservative 
management for older adults varies nationally, and depends partly on the degree to which 
conservative management is an established pathway within each unit (9,10).  Such pathways include 
careful monitoring, interventions to delay progression of kidney disease, and management of uraemia 
and burdensome symptoms including, but not limited to: fatigue, anorexia, nausea and vomiting, pain 
and pruritis (11,12). People with conservatively managed end-stage kidney disease have considerable 
symptom control needs, similar to advanced cancer populations (12). Longitudinal research has shown 
a sharp increase in symptom distress and health related concerns for patients with conservatively 
managed kidney disease in the last two months of life (13). 
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The impact of chronic illness or long-term conditions upon the individual and those close to them has 
long been recognised.  The ‘biographical disruption’ experienced often requires a fundamental 
rethinking of one’s identity, including plans and expectations (14).  Chronic illness is also associated 
with loss of self, or former self, and suffering, often resulting in withdrawal and isolation (15). The 
coping strategies that individuals develop, however, are influenced by their perceptions and 
interpretations of their illness (16).    
 
Research has highlighted the physical, social and psychological impact of kidney disease upon 
individuals (17-19), but has focused primarily on those in receipt of dialysis or transplant. The limited 
research into the experiences of those in receipt of conservative kidney management has focused on 
reasons for choosing that pathway (20-24), including communication and information provision, 
rather than the impact and understanding of their illness thereafter.  This study therefore aimed to 
explore: the experiences of older adults living with kidney disease that was being managed 
conservatively to examine: the impact of their illness, including the impact over time; and their 
understanding of the illness to inform clinical practice and policy.   
 
MATERIALS AND METHODS 
Design 
Secondary analysis of qualitative interview data. According to the typology of secondary analyses, this 
study represents a ‘supplementary analysis’ whereby the analysis focuses on emergent themes which 
were not addressed, or only partially addressed, by the primary analysis (25). 
 
Setting 
Participants were recruited from three renal units across South London and the South East of England, 
as part of a larger longitudinal study mixed methods (13).  Participation in the larger study included 
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consent for access to medical records, sharing of demographic information, a longitudinal quantitative 
survey (data from which are reported elsewhere (13)), and a single in depth qualitative interview 
undertaken in 2007 (secondary analysis of these interview data are reported in the current paper).   
 
 
 
Governance 
Ethical approval for the study was received by King’s College Hospital Research Ethics Committee 
(COREC: 04/03/092).  Local R&D and ethical approvals were acquired at each site. As the 
supplementary analysis of the data undertaken fell within the broad aims and objectives of the original 
study, no further approvals were required. 
 
Sampling 
Participants were purposively sampled for diversity by: age, co-morbidity (assessed using the Charlson 
Comorbidity index (26) modified for renal patients which excludes renal diagnosis and age from the 
scoring (27) and functional status (assessed using the Karnofsky Performance Status (28)). 
 
Inclusion Criteria: adults (>18 years) under the care of nephrologists with stage 5 CKD with eGFR ≤ 15 
mL/minute AND confirmed (by nephrologist) decision for conservative management (management 
without dialysis or  renal replacement therapy).  
Exclusion Criteria: lacking capacity to give consent to participate in the study.  
 
Recruitment 
Potentially eligible patients were identified by their clinicians, after assessment of their capacity at a 
clinic appointment, and given verbal and written information about the study. Clinicians sought 
permission for the researcher (FM) to make contact, and the preferred means of that contact. At least 
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24 hours after this first approach, the researcher contacted those who had expressed an interest in 
participation. Only one of the participants who was approached declined interview, as they felt too 
unwell. For all others a further appointment was then made, at the patient’s preferred location, at 
which written informed consent was taken to participate in the study, and the interview conducted. 
Recruitment continued until data saturation was achieved and no new themes, related to the aims 
and objectives of the original study, were emerging from subsequent interviews. 
 
Interviews 
Qualitative interviews were chosen to allow in-depth exploration of the illness experience for older 
adults living with kidney disease. A topic guide was developed, and piloted with three participants 
before being finalised (pilot interview data not included). In-depth interviews were conducted in the 
participant’s preferred location (all in their usual place of residence), to explore their experiences of 
the illness, the impact of their illness and symptoms, and their involvement in decision-making. For 13 
interviews, only the patient was present in the room for the interview; the remaining seven 
participants chose for their spouse or a relative to remain in the room.  All interviews were conducted 
by FM, a palliative care clinician. She was not known to the participants, was not involved in their care, 
and was introduced as a researcher. Interviews were audio recorded, transcribed verbatim and 
anonymised. Field notes were also taken at the time of the interview and immediately after, to capture 
contextual factors. No repeat interviews were undertaken, and transcripts were not returned to 
participants for comments.  
 
Analysis 
Interviews were transcribed verbatim, and transcripts were anonymised with allocation of culturally 
appropriate pseudonyms.  The study was positioned within a subtle realist paradigm which assumes 
that there is an objective reality, but that it can only be understood through an individual’s perspective 
of it (29). Interviews were analysed inductively using thematic analysis (30,31), which involved six 
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steps: familiarisation; coding; searching; reviewing; and defining themes; and reporting. This method 
was chosen as it offers the researcher an accessible and theoretically flexible approach to analysing 
qualitative data, shaped to the research question and epistemology (32). The researcher (FM) had not 
previously undertaken in-depth interviews, although had completed an intensive training course at 
the National Centre for Social Research to develop these skills. Early transcripts were critically 
reviewed by an independent experienced qualitative interviewer, to provide feedback and to refine 
techniques.  Analysis was further discussed and refined by FM, KB and LS. Analysis was supported by 
QSR NVivo qualitative data analysis software.  
 
RESULTS 
Participants 
Twenty older people (>65) living with kidney disease were interviewed.  The participants: had a 
median age of 82 years (range 69-95); 11 were men and nine women; 18 were of white ethnicity, one 
black Caribbean, and one other ethnicity (ethnicity was categorised according to those used in UK 
Renal Registry report); eight were married, nine were widowed, and three were single; ten were living 
alone, seven with their spouse, two with family (both with daughters), and one in a nursing home (see 
table 1). Median Karnofsky Performance Status Score was 60% (range 40-80%) (28), and median 
modified Charlson Comorbidity Index Score (which excludes renal diagnosis and age from the scoring) 
was 4 (range 4-8) (27).The duration of the interviews ranged from 38 to 74 minutes. 
 
Insert table 1 here 
 
Findings 
Participants described the challenges of living with kidney disease, particularly in terms of its hidden 
nature.  They described it as invisible and intangible, struggling to attribute symptoms to the illness, 
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whilst also feeling disconnected from it.  This combination of invisibility and intangibility, alongside 
the unpredictable nature of the illness, impacted heavily on individuals’ quality of life.   
 
Invisibility 
In expressing their experience of the illness, kidney disease was described by participants as a ‘hidden’ 
or ‘invisible’ illness. Participants made reference, with varying degrees of detail, to the perception that 
they were in the grip of something unseen. Jack, for instance, gave a graphic description of his kidney 
disease as an invisible illness. 
 
‘Like there’s something bubbling along in your blood that you don’t know quite what it will 
do, and you can’t see it.’(Jack, 84) 
 
Several participants contrasted kidney disease with other illnesses that they had experienced, pointing 
out the lack of form or identity for themselves or others to grasp. Jean described it as something 
hidden from her, with ‘nothing to show for it’, contrasting it with her (severe) arthritis that was visible 
in her hands and knees. 
 
‘There isn’t anything like I could say ‘this is the kidney problem doing this’ – it is all a bit more 
silent, going along there but without me really knowing, brewing away but nothing to see 
really …. I mean, they tell you the kidney isn’t good, but well … how do I know? There’s 
nothing to show for it, is there?... I’m not to know, am I? It’s kind of hidden, I don’t know it’s 
there.’ (Jean, 81) 
 
The lack of form and invisibility of kidney disease was further underpinned by descriptions of the 
illness almost as a ‘spectre’ or ‘being’, which would ‘creep up on you’, giving it agency and control over 
individuals’ actions.   
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‘Yes, and you don’t notice it, for a while you don’t really notice that you’re giving things up, 
it kind of creeps up on you, and then suddenly you do things like, a major one was why the 
hell get dressed when it takes me an hour to get dressed, why not just stay in my dressing 
gown.’ (Charles, 77) 
 
The unpredictability and lack of control associated with the illness was particularly challenging for 
George, who described being ‘in the hands of a mystery’. 
 
‘It’s like it’s some vis… invisible thing going on, and we don’t know. I mean they know the 
kidneys is bad, don’t they, but why does it go up and down and why does it, it cause all these 
problems? We’re in the hands of a mystery, I think.’ (George, 95) 
 
Intangibility 
A further extension of the invisibility of the kidney disease involved challenges in attributing symptoms 
to the illness. Participants described not knowing whether it was the illness causing symptoms or 
problems, whether they were age-related, or caused by other co-morbid conditions. This contributed 
to the sense of intangibility of the illness, as described by Grace. 
 
‘But I don’t know if that be kidney or not. Me heart’s bad and me breathing sometimes, and 
me legs play me bad at night. It could be all that, or somethin’ else, I don’ know (laughs)’. 
(Grace, 73) 
 
Other participants were also uncertain, not in describing the symptoms, but in knowing what had 
caused them. Some, such as Harold, who was 82, included their age as a possible reason for symptoms 
or problems. 
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“Another thing is I find I get very tired these days, I don’t know whether it’s that [meaning 
his kidney disease] or old age, I mean, you know, I’ve never been this age before’. (Harold, 
82) 
 
This uncertainty in attribution contributed to participants’ sense of a loss of control. Not only could 
they do little about the effects of the illness, but neither could participants explain what was causing 
them. This in turn influenced their feelings towards their illness and their perception of other people’s 
attitudes towards them.   
 
‘With my kidneys… it’s, well… hard to say, I just feel tired and no energy, and generally not 
myself, all vague and sounds like I’m just… complaining or something. Making a fuss about 
nothing (laughs)’ (Donald, 89) 
 
The loss of control experienced by individuals was exacerbated by the unpredictable nature of kidney 
disease, which severely impacted on their ability to complete or plan day-to-day activities, negatively 
affecting their quality of life. Specifically, some individuals described not being able to predict a 
deterioration from one day to the next. 
 
‘The worst of it is, I never quite know how I’m going to be. Sometimes I can get up and I’ll be 
fine, it will be a good day, and that will carry on for a bit, and then out the blue, it all goes, 
like I’ve run out of petrol or something, and there’s nothing in the tank. I can feel unwell for 
days then, but I never really know why it’s like that, this way, that way, can’t tell how I’ll be.’ 
(Florence, 82) 
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The physical impact of kidney disease was also described as vague or intangible, beyond tiredness or 
fatigue, almost as a weight, holding you down, suspending your ability to carry out activities.   
 
‘It’s hard to describe…. It’s rather like someone put lead weights on your shoulders or 
something, you just can’t get up and get going. It runs through everything, all the time. 
Sometimes it’s not so bad for a few weeks, and I think maybe I can do a few things, then 
suddenly it’s back again, and I can’t get going…’ (Betty, 79) 
 
This sense of being held down was also described as a loss of ‘get up and go’, lack of ‘impetus’, feeling 
they had no ‘fuel in the tank’, or ‘lifelessness’.  This effect was pervasive, impacting on all aspects of 
daily living, and the burden was exacerbated due to the unpredictability of the illness. 
 
‘The energy levels too, it was just steadily getting worse. Harder to do things, like I said, it’s 
hard to explain, but it was very difficult to say ‘I’m going to do this,’ and then do it. Normally 
you don’t think of it, you just get on and do, don’t you, but here I was, spending 20, 30 
minutes saying ‘I’m going to do’ and then still not doing, oh, even the simplest of things.’ 
(Franklyn, 86) 
 
For many the stark contrast between their life now and prior to their illness was overwhelming, 
particularly due to the often sudden deterioration affecting all aspects of their life. 
 
‘It has affected me terrible. Yes, you know. Nothing is the same … I don’t have the strength 
or the energy any more, it makes me feel useless, I couldn’t do what I wanted to do any 
more, but, there you are, you know what I mean, it’s so bad, I mean now I can’t even write, 
I can’t write properly …. I don’t know. It just seems to have struck me right down, it just 
came down like a ton of bricks, you know, it came right down on top of me.’ (Dorothy, 84) 
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Disconnectedness 
The invisible nature of the disease was also associated with a feeling of disconnectedness from it.  
Donald felt it was professionals who were telling him of his illness, but that this did not correspond to 
the evidence from his own senses; as he said, ‘can’t see it, don’t feel it’. 
 
‘I dunno, dunno as it has affected me. Can’t pin anything down, that’s what I said to Dr (GP’s 
name). Can’t see it, don’t feel it. Wouldn’t know about it, but for them…. It’s like someone 
tells you… your kidneys are bad… but it’s nothing to do with you, you have to believe them.” 
 
And he later went on to say:  
“If it’s me heart, then I might get pain, alright I don’t know if it’s indigestion or what, but I get a 
pain. With my kidneys… it’s, well… hard to say, I just feel tired and no energy.’ (Donald, 89) 
 
Others felt unable to pinpoint the illness as a specific cause, and relied on professionals to tell them 
what was happening. 
 
‘But it’s hard, if you have a pain in your back, you know it’s your back, if you have a muscle 
go in your hand, it’s in your hand. But you don’t know what your kidneys are doing do you, 
so it’s hard to say anything much about them, you have to go on what they [clinicians] say 
to you, with them bloods and that what they take.’ (Alice, 82) 
 
The invisibility and intangibility of the illness fueled the sense of disconnectedness from it.  
Collectively, these resulted in challenges in attributing symptoms to the kidney disease, reduced ability 
to plan and engage in activities, and poor quality of life.   
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DISCUSSION 
This is one of relatively few studies to examine the experience of older adults living with end-stage 
kidney disease in receipt of conservative kidney management.  Participants described the invisibility 
and intangibility of kidney disease, the challenges of attributing symptoms to the disease, and the 
unpredictable, and often sudden, nature of deterioration over time.  They described a spectre-like 
presence or force, sapping their energy and holding them down.  For some, it was hard to differentiate 
the symptoms of the illness from characteristics of ageing, resulting in challenges in illness attribution, 
and a sense of disconnectedness from the illness.   
 
Challenges in illness attribution have been recognised in other invisible illnesses including 
osteoporosis, where lack of symptoms created doubt and ambivalence regarding diagnosis (33), SLE 
(systemic lupus erythematosus) where invisibility had detrimental effects on adjustment (34), and 
COPD where invisible signs of deterioration were not recognised by professionals (35).  Indeed, as in 
the present study, where the condition is perceived as abstract, this impacts on the ability to make 
sense of and cope with illness (16).  The invisibility and intangibility of kidney disease resulted in 
participants’ lack of understanding of their illness, uncertainty, and a resultant inability to attribute 
symptoms and concerns to the illness.  This was associated with a loss of self (15) to a liminal state 
between illness and wellness (36,37), and a lack of access to the sick role (38), and the associated 
rights and obligations. The challenges of managing uncertainty in the context of advanced illness have 
also been recognised in cancer, heart failure, COPD and liver disease.  Better understanding of the 
patient’s goals and temporal focus (present or future), alongside exploration of their information 
needs and engagement with illness is critical to enable open and honest discussions about future care 
and preferences (39). Indeed, in the present study although participants spoke about deterioration 
more broadly and referred implicitly to their deterioration and death, very few spoke overtly about 
end of life care or used terms of this type. 
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Previous studies have recognised the variation in understanding of the nature and purpose of 
conservative kidney management across the UK (9,10). This disparity often appears to stem from 
inadequate communication about: the distinction between conservative care and more interventional 
approaches; prognosis; and the palliative nature of conservative care (40). Indeed nephrologists 
describe a reluctance to open discussions about prognosis with their patients until a deterioration is 
evident, due to long established relationships with patients and to avoid causing distress (41,42). The 
present study supports a need for improved communication, education and support regarding 
conservative care pathways, at the point of critical decisions, including: expectations with regard to 
symptoms and impact of the disease upon the lifeworld, alongside consideration of the burden of 
dialysis.  Research has highlighted that nephrologists underestimate the presence and severity of 
symptoms for haemodialysis patients (43).  It is critical that regular assessment of conservatively 
managed patients includes psychological, social and spiritual domains, alongside physical concerns, to 
ensure that: symptoms and concerns are recognised and addressed.  Moreover, it is essential that 
adjunct services to provide psychological, social and spiritual support are equally available to 
conservatively managed patients who may rarely attend the hospital, as they are for those attending 
regularly for dialysis.   
 
Strengths and Limitations 
This study has both strengths and limitations. The study sample represents a maximum variation 
sample, with regard to age, living situation, levels of co-morbidity and functional status, which 
adequately reflects the variability within this population. As this is a qualitative study, it does not seek 
for findings to be generalisable, however findings would be transferable to other sites with aging end-
stage kidney disease populations. Most participants in the study were of white ethnicity, reflecting 
the UK population and the catchment population for the three renal units. Further interviews with 
individuals from Black, Asian and minority ethnic communities would have increased the 
transferability of these findings. Seven individuals chose to undertake interviews with a family 
15 
 
member present in the room.  Whilst they did not participate in the interviews, it is possible that their 
presence may have influenced some responses to questions.  However, we chose to undertake 
interviews in line with the preferences of each individual, some of whom preferred to have someone 
else present for support.  The data for this study were originally collected in 2007, since which time 
conservative management has become a more accepted component of renal care. However there is 
recent evidence of significant variability in service delivery across renal units (44), and there continues 
to be a lack of research exploring the lived experiences of people living with conservatively managed 
kidney disease.  Our findings are therefore still novel and highly relevant. As a secondary 
(supplementary) analysis of an existing dataset, it was not possible to undertake an iterative process 
of recruitment and analysis, and therefore data saturation was more challenging to assess.  The 
original study addressed wider aims related to the experience of conservative kidney care, with 
themes across broader domains.  Primary research focusing specifically on the invisibility and 
intangibility of kidney disease may extend our findings.  Given the social and psychological impact of 
end-stage kidney disease beyond the individual living with the disease, further interviews with 
informal caregivers, and healthcare professionals delivering conservative kidney care, would also be 
beneficial, to further examine the invisibility and intangibility of this condition. In addition, longitudinal 
qualitative work with diverse patient groups would enable further exploration of how perspectives 
and understandings of conservatively managed kidney disease evolve over time, to inform 
intervention development. 
 
CONCLUSION 
This original paper describes, for the first time, the profound invisibility and intangibility of the illness 
perceived by those people with end-stage kidney disease managed conservatively, without dialysis. 
Challenges in differentiating the burdensome symptoms of end-stage kidney disease from normal 
aging are shared with other illnesses, but the profound intangibility causes major challenges to 
individual’s sense of self and obstructs development of realistic hopes and aspirations (45). A sharp 
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increase in symptom distress and health concerns for those with conservatively managed kidney 
disease may suggest a marked deterioration or change in phase of illness, demonstrating the 
importance of recognition and management of symptoms (13).  However, differences between the 
patient’s interpretation of this intangible illness and its effects on their life, and the professional’s 
biomedical symptom focused approach, may preclude meaningful discussions about problems, 
concerns and future care (46).  Clinical services need to recognise the invisibility, intangibility, and 
related sense of disconnectedness, and address this through specific interventions focused on 
improving clinical assessment and communication, education, peer support, and professional support.  
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Table 1: Participant Characteristics 
Participants 20 
Gender 
Female 
Male 
 
11 
9 
Age 
<75 
75-79 
80-84 
≥85 
 
2 
5 
8 
5 
Marital Status 
Married 
Widowed  
Single 
 
8 
9 
3 
Renal Diagnosis 
Diabetes Mellitus 
Glomerulo-nephritis 
Renal vascular disease 
Unknown 
Other 
 
5 
3 
2 
9 
1 
Karnofsky Performance Status Score 
40% 
50% 
60% 
70% 
80% 
Median 
Range 
 
3 
3 
4 
7 
3 
60% 
40-80% 
Modified Charlson Comorbidity Index Score* 
2 
3 
4 
5 
6 
8 
Median 
Range 
 
2 
5 
5 
4 
3 
1 
4 
2-8 
 
* Charlson Comorbidity Index modified for renal patients which excludes renal diagnosis and age from 
the scoring(27). 
